Who to call at Path Fertility, and when
Fundz watches for the moments Path Fertility starts buying, and tells you who to reach.
- An alert the day Path Fertility raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Path Fertility, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Path Fertility. With Fundz connected, it knows.
Path Fertility receives $2M SBIR grant from NIH to develop epigenetic diagnostics for male fertility and cancer risk assessment.
Salt Lake CityBiotechnologyHealth CareGeneticsHealth DiagnosticsDescription
Path Fertility, a Salt Lake City-based molecular diagnostics company, received a $2M Direct to Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The grant will fund development and clinical validation of an epigenetic diagnostic for non-obstructive azoospermia (NOA) and associated cancer risk. Path Fertility's platform includes SpermQT, a clinically validated epigenetic sperm quality test, and NOA Guide, a diagnostic for predicting surgical sperm retrieval.
Quick answer
Path Fertility receives $2M SBIR grant from NIH to develop epigenetic diagnostics for male fertility and cancer risk assessment. (November 5, 2026). Path Fertility is based in Salt Lake City, Utah, United States.
- What agreement did Path Fertility announce on November 5, 2026?
- Path Fertility, a Salt Lake City-based molecular diagnostics company, received a $2M Direct to Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The grant will fund development and clinical validation of an epigenetic diagnostic for non-obstructive azoospermia (NOA) and associated cancer risk.
- What does Path Fertility do?
- Path Fertility is a Salt Lake City-based molecular diagnostics company advancing epigenetic testing for male fertility and reproductive health.
- Where is Path Fertility based?
- Path Fertility is based in Salt Lake City, Utah, United States.
- Which similar companies announced agreements around the same time?
- BioMarin Pharmaceutical (October 29, 2026), Quantum Cyber N.V. (November 12, 2026), M42 (October 23, 2026) and Neuratia Labs (October 21, 2026) also announced agreements within 45 days of Path Fertility.
Source: Fundz verified event record.
Other recent agreements in Genetics and Health Diagnostics
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026)
- Quantum Cyber N.V. Enters into Expanded Intellectual Property License Agreement with LightShift (November 12, 2026)
- M42 partners with Siemens Healthineers to transform healthcare in the Global South. (October 23, 2026)
- Neuratia Labs forms strategic partnership with CliniDataCue to bolster healthcare AI and Neuroscience Research. (October 21, 2026)
- PacBio and Verily Health Form Strategic Partnership to Enhance Long-Read Genomics for Biomedical AI. (October 19, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
Related People
Path Fertility signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.